FGF23 and chronic kidney disease: While definite conclusions as to its usefulness in the clinical field would require dedicated clinical trials, there is significant potential for this biomarker, as it has already been demonstrated that high FGF23 is associated with an increased risk of new-onset CKD and higher all-cause mortality afterwards [203].